论文部分内容阅读
目的探讨环氧化物酶-2(Cox-2)和PTEN/MMAC1在非小细胞肺癌中表达的相关性及其意义。方法应用免疫组化EnVision二步法检测50例非小细胞肺癌、30例癌旁正常肺组织中Cox-2和PTEN/MMAC1的表达。结果 50例非小细胞肺癌中Cox-2和PTEN/MMAC1阳性率分别为78%(39/50)和36%(18/50),30例癌旁正常肺组织Cox-2和PTEN/MMAC1阳性率分别为20%(6/30)和83.3%(25/30)。非小细胞肺癌组织中Cox-2阳性表达率显著高于癌旁正常肺组织,PTEN/MMAC1阳性率显著低于癌旁正常肺组织,Cox-2和PTEN/MMAC1蛋白表达呈负相关(P<0.05);Cox-2高表达和PTEN/MMAC1低表达与非小细胞肺癌临床分期、脉管浸润、淋巴结转移及患者生存期呈显著相关(P<0.05),与患者性别、年龄、肿瘤大小、组织学类型无关(P>0.05),PTEN/MMAC1与肿瘤组织分化相关(P<0.05),Cox-2与肿瘤组织分化无关(P>0.05)。结论 Cox-2和PTEN/MMAC1与非小细胞肺癌浸润转移,推测Cox-2和PTEN/MMAC1蛋白表达可共同作为非小细胞肺癌浸润、转移、预后的评估指标。
Objective To investigate the correlation between the expression of Cox-2 and PTEN / MMAC1 in non-small cell lung cancer and its significance. Methods The expressions of Cox-2 and PTEN / MMAC1 in 50 non-small cell lung cancer tissues and 30 adjacent normal lung tissues were detected by immunohistochemistry EnVision two-step method. Results The positive rates of Cox-2 and PTEN / MMAC1 were 78% (39/50) and 36% (18/50) in 50 non-small cell lung cancer tissues respectively. The positive expression of Cox-2 and PTEN / Rates were 20% (6/30) and 83.3% (25/30), respectively. The positive rate of Cox-2 in non-small cell lung cancer tissues was significantly higher than that in adjacent normal lung tissues. The positive rate of PTEN / MMAC1 in NSCLC was significantly lower than that in adjacent normal lung tissues (P <0.05). The expressions of Cox-2 and PTEN / MMAC1 were negatively correlated 0.05). The high expression of Cox-2 and the low expression of PTEN / MMAC1 correlated with the clinical stage, vascular invasion, lymph node metastasis and the survival of patients with NSCLC (P <0.05), but not with the gender, age, tumor size, (P> 0.05). PTEN / MMAC1 was correlated with tumor differentiation (P <0.05). Cox-2 had no correlation with tumor differentiation (P> 0.05). Conclusions The invasion and metastasis of Cox-2, PTEN / MMAC1 and non-small cell lung cancer suggest that the expression of Cox-2 and PTEN / MMAC1 together may be used as an index to evaluate the infiltration, metastasis and prognosis of non-small cell lung cancer.